Article: Botulinum toxin type B for gait freezing in Parkinson's disease.
Medical science monitor : international medical journal of experimental and clinical research
2004 Volume 10, Issue 7, Page(s) CR282–4
Abstract: Background: Freezing of Gait (FOG) can be a serious problem in Parkinson's disease (PD) and is usually refractory to medical treatment. Botulinum toxin (BTX) type A has been reported to relieve FOG in small open label studies.: Material/methods: We ... ...
| Abstract | Background: Freezing of Gait (FOG) can be a serious problem in Parkinson's disease (PD) and is usually refractory to medical treatment. Botulinum toxin (BTX) type A has been reported to relieve FOG in small open label studies. Material/methods: We performed a double-blind, placebo-controlled, parallel-group study using BTX-B injections on the soleus-gastrocnemius muscle complex of the predominantly affected leg in freezing. Patients were evaluated at baseline and monthly thereafter until endpoint was reached. UPDRS parts II and III, Visual Analog Scale (VAS), Clinical Global Impression Scale (CGIS) and Modified Webster Step-Seconds test were the used to measure efficacy. Results: 14 out of 17 patients screened with idiopathic PD and FOG refractory to medical treatment met inclusion criteria for the study. 9 patients were randomized to 5,000 U of BTX-B treatment and 5 patients to placebo. Our cohort had a mean age of 74 years, and average PD duration of 10 years. Based on the CGIS, 1 patient was much improved, 2 patients had minimal improvement, 9 were unchanged from baseline and 2 were minimally worse. There was no significant difference between the treatment and placebo arms in the number of patients improved versus unchanged. There were no significant differences between the treatment and placebo arms in the UPDRS II and III, VAS, or Modified Webster Step-Seconds scores between the treatment and placebo arms, at baseline and after treatment. Conclusions: 5,000 U of BTX-B injected in one leg did not significantly improve FOG. However, since the power of the study was low, a small beneficial effect may have been missed. |
|---|---|
| MeSH term(s) | Aged ; Aged, 80 and over ; Anti-Dyskinesia Agents/administration & dosage ; Botulinum Toxins/administration & dosage ; Botulinum Toxins, Type A ; Double-Blind Method ; Gait ; Gait Disorders, Neurologic/drug therapy ; Gait Disorders, Neurologic/etiology ; Humans ; Injections, Intramuscular ; Middle Aged ; Muscle, Skeletal/drug effects ; Muscle, Skeletal/physiology ; Parkinson Disease/complications ; Parkinson Disease/drug therapy ; Severity of Illness Index ; Treatment Outcome ; Walking |
| Chemical Substances | Anti-Dyskinesia Agents ; rimabotulinumtoxinB (0Y70779M1F) ; Botulinum Toxins (EC 3.4.24.69) ; Botulinum Toxins, Type A (EC 3.4.24.69) |
| Language | English |
| Publishing date | 2004-07 |
| Publishing country | United States |
| Document type | Clinical Trial ; Journal Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't |
| ZDB-ID | 1439041-3 |
| ISSN | 1643-3750 ; 1234-1010 |
| ISSN (online) | 1643-3750 |
| ISSN | 1234-1010 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.A 4924: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.